Showing 6611-6620 of 19348 results for "".
Dr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://reachmd.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingJournal Club: Biologics for Young Children
https://reachmd.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RJournal Club: Pediatric Treatment Adherence
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-pediatric-treatment-adherence/32401/Practical Dermatology Editorial Board members Lawrence Eichenfield, MD, FAAD, Jason Hawkes, MD, MS FAAD, discuss the article "Treatment Adherence in Pediatric Atopic Dermatitis: A Systemic Review," from Pediatric Dermatology as well as their favorite strategies for treatment adherence and the impactJournal Club: Dupilumab and Risk of Malignancy
https://reachmd.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseQ&A: The Rise of Peptides
https://reachmd.com/programs/modern-aesthetics/QA-Rise-Peptides/32712/Kay Durairaj, MD, talks about the potential applications for peptides in aesthetic medicine, challenges in implementing them, and more.Skin Flooding: A Dermatologist’s Guide to the Latest Hydration Hack
https://reachmd.com/programs/modern-aesthetics/Skin-Flooding-Dermatologist-Guide-Latest-Hydration-Hack/32709/The ever-evolving world of social media throws up new skincare trends at a dizzying pace. One of the latest buzzwords is “skin flooding,” referring to a not-so-new technique that promises to deliver ultra-hydrated, plump skin. While this might pique the interest of your patients, being equipped withCanadian Perspective: Drs. Bhatia, Sapijaszko, and Kaufmann
https://reachmd.com/conferences/maui-derm-hawaii-2025/canadian-perspective-drs-bhatia-sapijaszko-and-kaufmann/32695/Neal Bhatia, MD, speaks with Canadian Dermatology Association vice president Mariusz Sapijaszko, MD, FAACS, and former American Academy of Dermatology president Mark Kaufmann, MD, about different perspectives on advocacy in dermatology, including the use of patient stories.Skin of Color Session: Dr. Taylor
https://reachmd.com/programs/practical-dermatology/skin-of-color-session-dr-taylor/32674/Susan Taylor, MD, summarizes her presentation during the "Skin of Color Session" at Maui Derm 2025, including a discussion of photoprotection for patients with vitiligo, hyperpigmentation, and melasma.Psoriasis Update 2025: Dr. Gelfand
https://reachmd.com/programs/practical-dermatology/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.The Aryl Hydrocarbon Receptor and Lupus: Diagnostic and Therapeutic Advancements
https://reachmd.com/programs/living-rheum/the-aryl-hydrocarbon-receptor-and-lupus-diagnostic-and-therapeutic-advancements/28634/Explore the connection between the aryl hydrocarbon receptor and systemic lupus erythematosus and uncover its potential to improve treatment options.